Osimert — Osimertinib 80 mg, 30 Tablets

Osimert is formulated as film-coated tablets for oral administration. Each tablet contains:

• Active Ingredient: Osimertinib mesylate — equivalent to 80 mg of free-base osimertinib.
• Inactive Core Excipients: Mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and sodium stearyl fumarate (optimized for uniform drug dissolution).
• Film Coating: Polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, yellow iron oxide, red iron oxide, and black iron oxide.

Pharmacodynamics: Osimertinib is a tyrosine kinase inhibitor (TKI) that binds covalently and irreversibly to specific mutant forms of EGFR (L858R, del19, and the double mutation T790M) at clinical concentrations. It effectively prevents auto-phosphorylation of the EGFR receptor, halting the downstream signaling pathways responsible for the uncontrolled replication and survival of neoplastic lung tissue.

Pharmacokinetics: Following oral administration, peak plasma concentration (Cmax) is achieved within a median of 6 hours (range 3–10 hours). Absorption is gradual and unaffected by food intake. The apparent volume of distribution is highly extensive, and plasma protein binding is exceptionally strong (approximately 98.5%). Osimertinib undergoes hepatic clearance primarily mediated by CYP3A4 and CYP3A5, yielding active metabolites AZ5104 and AH10407. The terminal half-life (T1/2) is approximately 48 hours, with primary excretion via feces (68%) and to a lesser extent via urine (14%).

Osimert 80 mg is indicated for adult patients under the following therapeutic indications:

• 🔹 First-Line Treatment: Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions or exon 21 L858R mutations.
• 🔹 Second-Line Treatment: Patients with metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after prior EGFR TKI therapy.
• 🔹 Adjuvant Therapy: Postoperative adjuvant treatment following complete tumor resection in patients with early-stage EGFR mutation-positive NSCLC to reduce recurrence rates.

Osimert treatment must be supervised and adjusted by a qualified medical oncologist:

• Standard Regimen: The recommended therapeutic dose is 80 mg (1 tablet) taken orally once daily. Tablets should be taken at the same time every day, independent of food. Swallow the tablet whole with a glass of water.
• Swallowing Difficulties: The tablet can be dispersed in 50 mL of non-carbonated water without crushing. Stir until dispersed and drink immediately. Rinse the glass with an additional 50 mL of water and drink the contents to ensure the full dose is administered.
• Duration and Modification: Therapy is continued until disease progression or unacceptable toxicities occur. Severe adverse events may require the supervising physician to reduce the daily dose to 40 mg.

The clinical administration of Osimert is contraindicated or must be strictly monitored under the following parameters:

• ⛔ Hypersensitivity: Known history of hypersensitivity to osimertinib or any tablet core excipients.
• ⛔ Pregnancy and Lactation: Highly toxic to the developing fetus; contraindicated in pregnant women. Breastfeeding must be suspended entirely during therapy.
• ⛔ Concomitant St. John's Wort: Herbal remedies containing Hypericum perforatum are contraindicated as they drastically diminish osimertinib efficacy.
• ⚠️ With Caution: Patients with a history of interstitial lung disease (ILD), congenital long QT syndrome, or severe hepatic and renal functional impairments.

Osimertinib exhibits a sensitive drug interaction profile governed by hepatic metabolic enzymes:

• ❌ Strong CYP3A4 Inducers: Co-administration with rifampicin, phenytoin, carbamazepine, or phenobarbital reduces osimertinib exposure by more than 70%, rendering the cancer therapy ineffective. Concomitant use is contraindicated.
• ⚠️ BCRP and P-gp Substrates: Osimertinib can increase the systemic exposure of drugs cleared by these transporters (e.g., digoxyn, dabigatran, rosuvastatin), requiring careful toxicity monitoring.
• ⚠️ QTc-Prolonging Agents: Avoid combining with Class I or III antiarrhythmics or certain fluoroquinolones to minimize cardiac risks.

Safety parameters and reproductive guidelines during Osimert therapy:

• For Female Patients: Women of childbearing potential must utilize highly effective, reliable contraception throughout the treatment course and for at least 2 months following the final dose of Osimert.
• For Male Patients: Male patients with female partners of reproductive potential must use dependable barrier methods of contraception during treatment and for at least 4 months after the final dose.
• Lactation: Do not breastfeed during treatment and for at least 2 weeks after the last dose, due to potential risks to the infant.

Adverse reactions associated with Osimert 80 mg are classified by organ systems and frequency:

• 🟢 Dermatological (Very Common): Dry skin, pruritus, skin rash (including acneiform dermatitis), toxic stomatitis, and paronychia (nail bed inflammation).
• 🟡 Gastrointestinal: Diarrhea (most common reaction, manageable with loperamide), nausea, decreased appetite, and vomiting.
• 🟠 Hematological Alterations: Mild-to-moderate thrombocytopenia (reduced platelets), leukopenia (reduced white blood cells), and lymphopenia.
• 🔵 Severe Risks (Rare, requires immediate drug discontinuation): Interstitial lung disease (ILD/pneumonitis), significant QTc interval prolongation on ECG, and cardiomyopathy (reduced left ventricular ejection fraction).

Overdose risks and supportive emergency measures for Osimert:

• Symptoms: There is no specific clinical pattern for osimertinib overdose; however, it is characterized by an acute exacerbation of known toxicities, including severe diarrhea, critical dehydration, acute bone marrow suppression, and cardiac conduction abnormalities.
• Treatment: There is no direct antidote. Suspected overdoses require immediate hospitalization, gastric lavage, administration of activated charcoal, continuous ECG monitoring, and aggressive supportive intravenous fluid and electrolyte therapy.

Storage instructions to maintain the biochemical stability of Osimert:

• 🌡️ Temperature: Store in a dry environment shielded from direct sunlight at a controlled room temperature not exceeding 30 °C.
• 👶 Safety: Keep the bottle tightly sealed in its original box, safely out of reach of children and pets. This is a hazardous cytotoxic drug; do not dispose of unused tablets in domestic trash or wastewater systems.
• ⏳ Shelf Life: 3 years. Do not use the medication after the expiration date printed on the carton and bottle label.

Genuine Osimert 80 mg by Everest Pharmaceuticals features a comprehensive multi-layered physical and digital security system (protective measures) to protect patients against counterfeits:

• 🛡️ Official Hologram Seal: The top opening flap of the cardboard carton is sealed with a genuine, metallized holographic sticker depicting the Everest company logo. When tilted under light, the hologram reveals distinct rainbow gradients, unique protective background patterns, and micro-text. It is impossible to open the carton without permanently tearing or breaking this seal.
• 🔑 Scratch-and-Verify Security Code: A dedicated verification sticker with a silver scratch-off layer (similar to a lottery ticket) is located on the side or back of the box. Scratching this layer gently with a coin reveals a unique, confidential alphanumeric security code. To verify, go to the manufacturer's official website www.everestpharmaceuticals.com, navigate to the "Verify Product" or "Authentication" section, and enter the code. The system will instantly verify if the pack is a genuine, registered product and if it is being checked for the first time.
• 🔗 QR Code Quick Authentication: Next to the scratch-off panel, there is a QR code. Scanning this QR code with a smartphone camera automatically redirects the user to the verification portal on Everest's official website, with the unique security code already auto-filled for quick confirmation.
• 🔒 Induction Bottle Seal & Shrink Wrap: The thick white polymer bottle inside is sealed with a child-resistant safety cap (push down and turn). Underneath the cap, the bottle neck is hermetically sealed with a thick tamper-evident foil membrane featuring hot-melt sealing technology (often printed with the company logo or "Sealed for your protection"). Additionally, the bottle cap is encased in a transparent protective shrink-wrap sleeve.
• 🔍 Tactile Relief and Laser Batch Printing: The product name "Osimert" and the "Everest" logo on the carton are printed using premium embossed ink, making them clearly raised and tactile to the touch. The batch number (B.No.), manufacturing date (Mfd.Date), and expiration date (Exp.Date) are printed on the bottle label and permanently laser-etched onto the bottom of the cardboard box. The printed details on the carton must perfectly match the details on the bottle label.